Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Glatiramer→

Glatiramer Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
147245-92-9
Molecular formula
[C9H11NO2 . C6H13NO2 . C5H9NO4 . C3H7NO2]x
Molecular weight
~5000 to ~9000 g/mol
Drug class
Synthetic polypeptide immunomodulatormultiple sclerosis disease-modifying therapy
Mechanism of action
The mechanisms of action are not fully understood. Glatiramer acetate is thought to modulate immune responses, including effects on antigen-presenting cells and T-cell populations, shifting responses toward anti-inflammatory phenotypes and potentially reducing CNS-directed inflammatory activity.
Indications / reported uses
  • Treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, under the applicable product label

Sources: US DailyMed — Glatiramer acetate · NLM MeSH — Glatiramer acetate · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Glatiramer Environmental Risk Assessment (ERA) (the Glatiramer ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.